Triple threat: new combo therapy targets Hard-to-Treat melanoma

This phase II trial is testing two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or cannot be removed by surgery. One group receives nivolumab (immunotherapy) plus dabrafenib and trametinib (targeted therapy); the other receives nivolumab plus encorafenib and binimetinib. The goal is to see how well these combinations shrink tumors and what side effects occur. The study enrolls 52 participants whose melanoma has progressed after prior PD-1 therapy.